Treating sickle cell disease by targeting HbS polymerization

被引:186
作者
Eaton, William A. [1 ]
Bunn, H. Franklin [2 ]
机构
[1] NIDDK, Chem Phys Lab, NIH, Bldg 5,Room 104,9000 Rockville Pike, Bethesda, MD 20892 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
基金
美国国家卫生研究院;
关键词
GARDOS CHANNEL BLOCKER; FETAL-HEMOGLOBIN; DELAY-TIME; POSSIBLE DETERMINANT; DEOXYHEMOGLOBIN-S; NIPRISAN NIX-0699; CRYSTAL-STRUCTURE; OXYGEN-BINDING; DOUBLE-BLIND; IN-VITRO;
D O I
10.1182/blood-2017-02-765891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to form fibers that make red cells less flexible, most drugs currently beingassessedin clinical trials are targeting the downstream sequelae of this primary event. Less attention has been devoted to investigation of the multiple ways in which fiber formation can be inhibited. In this article, we describe the molecular rationale for 5 distinct approaches to inhibiting polymerization and also discuss progress with the few antipolymerization drugs currently in clinical trials.
引用
收藏
页码:2719 / 2726
页数:8
相关论文
共 108 条
[1]   5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells [J].
Abdulmalik, O ;
Safo, MK ;
Chen, QK ;
Yang, JS ;
Brugnara, C ;
Ohene-Frempong, K ;
Abraham, DJ ;
Asakura, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (04) :552-561
[2]  
ABRAHAM DJ, 1991, BLOOD, V77, P1334
[3]   Sickle cell disease in a carrier with pyruvate kinase deficiency [J].
Alli, Nazeer ;
Coetzee, Marius ;
Louw, Vernon ;
van Rensburg, Ben ;
Rossouw, Gerrit ;
Thompson, Lisa ;
Pissard, Serge ;
Thein, Swee Lay .
HEMATOLOGY, 2008, 13 (06) :369-372
[4]   2015 Clinical trials update in sickle cell anemia [J].
Archer, Natasha ;
Galacteros, Frederic ;
Brugnara, Carlo .
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (10) :934-950
[5]   Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease [J].
Ataga, K. I. ;
Kutlar, A. ;
Kanter, J. ;
Liles, D. ;
Cancado, R. ;
Friedrisch, J. ;
Guthrie, T. H. ;
Knight-Madden, J. ;
Alvarez, O. A. ;
Gordeuk, V. R. ;
Gualandro, S. ;
Colella, M. P. ;
Smith, W. R. ;
Rollins, S. A. ;
Stocker, J. W. ;
Rother, R. P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (05) :429-439
[6]   Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia [J].
Ataga, Kenneth I. ;
Smith, Wally R. ;
De Castro, Laura M. ;
Swerdlow, Paul ;
Saunthararajah, Yogen ;
Castro, Oswaldo ;
Vichinsky, Elliot ;
Kutlar, Abdullah ;
Orringer, Eugene P. ;
Rigdon, Greg C. ;
Stocker, Jonathan W. .
BLOOD, 2008, 111 (08) :3991-3997
[7]   The trials and hopes for drug development in sickle cell disease [J].
Ataga, Kenneth I. ;
Stocker, Jonathan .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) :768-780
[8]   Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043) [J].
Ataga, Kenneth I. ;
Reid, Marvin ;
Ballas, Samir K. ;
Yasin, Zahida ;
Bigelow, Carolyn ;
St James, Luther ;
Smith, Wally R. ;
Galacteros, Frederic ;
Kutlar, Abdullah ;
Hull, James H. ;
Stocker, Jonathan W. .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (01) :92-104
[9]  
Ataga Kenneth I, 2007, Hematology Am Soc Hematol Educ Program, P91
[10]   Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders [J].
Bauer, Daniel E. ;
Kamran, Sophia C. ;
Orkin, Stuart H. .
BLOOD, 2012, 120 (15) :2945-2953